デフォルト表紙
市場調査レポート
商品コード
1482462

イブプロフェンの静脈内投与市場:適応症別、強さ別、年齢層別、流通チャネル別、地域別

Intravenous Ibuprofen Market, By Indication, By Strength, By Age Group, By Distribution Channel, By Geography


出版日
ページ情報
英文 160 Pages
納期
2~3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
イブプロフェンの静脈内投与市場:適応症別、強さ別、年齢層別、流通チャネル別、地域別
出版日: 2024年04月16日
発行: Coherent Market Insights
ページ情報: 英文 160 Pages
納期: 2~3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

世界の静脈内(IV)イブプロフェン市場は、2024年には69億1,000万米ドルと推定され、2031年には111億3,000万米ドルに達すると予測され、2024年から2031年までのCAGRは7%を示すと予測されています。

レポート範囲 レポート詳細
基準年 2023 2024年の市場規模 69億1,000万米ドル
実績データ 2019年~2023年 予測期間 2024年から2031年
予測期間2024年から2031年 CAGR: 7.00% 2031年の予測値 111億3,000万米ドル
図.静脈内(IV)イブプロフェン市場シェア(%)地域別、2024年
Intravenous Ibuprofen Market-IMG1

静脈内(IV)イブプロフェンは、数十年前から鎮痛・解熱に使用されています。非ステロイド性抗炎症薬(NSAID)であるイブプロフェンの静脈内製剤として、経口投与に比べて吸収と作用発現が速いです。静脈内(IV)イブプロフェンは、痛みや発熱を促進する体内のホルモン様物質であるプロスタグランジンの産生を阻害することにより作用します。静脈内投与では、中等度から重度の痛みを15分以内に緩和することができ、1回の投与で最大8時間効果が持続する可能性があります。世界の静脈内(IV)イブプロフェン市場は、静脈内投与による疼痛管理を必要とする疾患の増加や、他の鎮痛薬と比較した場合の利点により、近年安定した成長を遂げています。

市場力学:

整形外科疾患や術後痛を患う高齢者人口の増加、発熱・疼痛疾患の有病率の増加、経口NSAIDsに対する静脈内(IV)イブプロフェンの優れた有効性などが、世界の静脈内(IV)イブプロフェン市場の成長を牽引しています。しかし、長期使用による消化管出血や腎毒性の潜在的リスクや、非オピオイド代替薬への嗜好性が、市場の成長を抑制すると予想されます。新たな適応症や剤形に対する有効性を評価する臨床試験が進行中であるため、有利なビジネスチャンスが見込まれます。

本調査の主な特徴

  • 本レポートでは、世界の静脈内(IV)イブプロフェン市場を詳細に分析し、2023年を基準年とした予測期間(2024年~2031年)の市場規模および複合年間成長率(CAGR%)を示します。
  • また、さまざまなセグメントにわたる潜在的な収益機会を明らかにし、この市場に対する魅力的な投資提案のマトリックスについて解説しています。
  • また、市場促進要因、抑制要因、機会、新製品の上市や承認、市場動向、地域別の展望、主要企業が採用する競争戦略などに関する重要な考察も提供しています。
  • 本レポートでは、世界の静脈内(IV)イブプロフェン市場における主な企業を、企業ハイライト、製品ポートフォリオ、主要なハイライト、業績、戦略などのパラメータに基づいてプロファイルしています。
  • 本レポートからの洞察により、マーケティング担当者や企業の経営陣は、将来の製品発売、タイプアップ、市場拡大、マーケティング戦術に関する情報に基づいた意思決定を行うことができます。
  • 世界の静脈内(IV)イブプロフェン市場は、投資家、サプライヤー、製品メーカー、流通業者、新規参入者、財務アナリストなど、この業界の様々な利害関係者に対応しています。
  • 利害関係者は、世界の静脈内(IV)イブプロフェン市場の分析に使用される様々な戦略マトリックスを通じて、意思決定が容易になります。

目次

第1章 調査の目的と前提条件

  • 調査目的
  • 前提条件
  • 略語

第2章 市場の展望

  • レポートの説明
    • 市場の定義と範囲
  • エグゼクティブサマリー
  • Coherent Opportunity Map(COM)

第3章 市場力学、規制、動向分析

  • 市場力学
    • 促進要因
    • 抑制要因
    • 機会
  • 影響分析
  • 市場動向
  • 最近の動向
  • 規制シナリオ
  • メーカー収益
  • 価格分析
  • 買収と提携のシナリオ
  • 製品の発売/承認
  • 資金調達と投資
  • PEST分析
  • ポーターの分析

第4章 世界の静脈内(IV)イブプロフェン市場、COVID-19 パンデミックの影響

  • 全体的な影響
  • 政府の取り組み
  • COVID-19市場への影響

第5章 世界の静脈内(IV)イブプロフェン市場、適応症別、2019年-2031年

  • 疼痛管理
  • その他

第6章 世界の静脈内(IV)イブプロフェン市場、強さ別、2019年-2031年

  • 100mg
  • 200mg
  • 400mg
  • 800mg

第7章 世界の静脈内(IV)イブプロフェン市場、年齢層別、2019年-2031年

  • 小児科
  • 大人

第8章 世界の静脈内(IV)イブプロフェン市場、流通チャネル別、2019年-2031年

  • 病院薬局
  • 小売薬局
  • オンライン薬局

第9章 世界の静脈内(IV)イブプロフェン市場、地域別、2019年-2031年

第10章 競合情勢

  • 企業プロファイル
    • Cumberland Pharmaceuticals Inc.
    • Hyloris Pharmaceuticals SA
    • Grifols, SA
    • Recordati Rare Diseases Inc.
    • XGEN PHARMACEUTICALS DJB, Inc.
    • AFT Pharmaceuticals
    • Laboratorios Valmorca
    • SGPharma Pvt. Ltd.
    • Wellona Pharma
    • Delex Pharma
    • Hikma Pharmaceuticals PLC

第11章 アナリストの推奨事項

  • アナリストの見解
  • 一貫した機会マップ

第12章 参考文献と調査手法

  • 参考文献
  • 調査手法
目次
Product Code: CMI6901

Global intravenous (IV) ibuprofen market is estimated to be valued at USD 6.91 Bn in 2024 and is expected to reach USD 11.13 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 7% from 2024 to 2031.

Report Coverage Report Details
Base Year: 2023 Market Size in 2024: US$ 6.91 Bn
Historical Data for: 2019 to 2023 Forecast Period: 2024 to 2031
Forecast Period 2024 to 2031 CAGR: 7.00% 2031 Value Projection: US$ 11.13 Bn
Figure. Intravenous (IV) Ibuprofen Market Share (%), By Region 2024
Intravenous  Ibuprofen Market - IMG1

Intravenous (IV) ibuprofen is used for pain relief and fever reduction for several decades. As an intravenous formulation of the nonsteroidal anti-inflammatory drug (NSAID) ibuprofen, it offers faster absorption and onset of action as compared to oral administration. Intravenous (IV) ibuprofen works by blocking the production of prostaglandins - hormone-like substances in the body that promote pain and fever. With intravenous delivery, it can provide relief for moderate to severe pain within 15 minutes and may be effective for up to 8 hours with a single dose. Global intravenous (IV) ibuprofen market has witnessed steady growth in recent years due to increasing prevalence of diseases requiring IV pain management and benefits over other analgesic options.

Market Dynamics:

Global intravenous (IV) ibuprofen market growth is driven by rising geriatric population suffering from orthopedic diseases and postoperative pain, growing prevalence of fever and pain conditions, and superior efficacy of IV ibuprofen over oral NSAIDs. However, potential risks of gastrointestinal bleeding and kidney toxicity with long-term use along with preference for non-opioid alternatives are expected to restrain the market growth. Ongoing clinical trials evaluating efficacy for new indications and formulations present lucrative opportunities.

Key Features of the Study:

  • This report provides in-depth analysis of the global intravenous (IV) ibuprofen market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year.
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
  • It profiles key players in the global intravenous (IV) ibuprofen market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
  • Key companies covered as a part of this study Cumberland Pharmaceuticals Inc., Hyloris Pharmaceuticals SA, Grifols, S.A., Recordati Rare Diseases Inc., XGEN PHARMACEUTICALS DJB, Inc., AFT Pharmaceuticals, Laboratorios Valmorca, SGPharma Pvt. Ltd., Wellona Pharma, Delex Pharma, and Hikma Pharmaceuticals PLC.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
  • Global intravenous (IV) ibuprofen market caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global intravenous (IV) ibuprofen market.

Detailed Segmentation-

  • By Indication:
    • Pain Management
    • Fever
    • Others
  • By Strength:
    • 100 mg
    • 200 mg
    • 400 mg
    • 800 mg
  • By Age Group:
    • Pediatrics
    • Adults
  • By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • By Region:
    • North America
    • Europe
    • Asia Pacific
    • Latin America
    • Middle East
    • Africa
  • Company Profiles:
    • Cumberland Pharmaceuticals Inc.
    • Hyloris Pharmaceuticals SA
    • Grifols, S.A.
    • Recordati Rare Diseases Inc.
    • XGEN PHARMACEUTICALS DJB, Inc.
    • AFT Pharmaceuticals
    • Laboratorios Valmorca
    • SGPharma Pvt. Ltd.
    • Wellona Pharma
    • Delex Pharma
    • Hikma Pharmaceuticals PLC

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snapshot, By Indication
    • Market Snapshot, By Strength
    • Market Snapshot, By Age Group
    • Market Snapshot, By Distribution Channel
    • Market Snapshot, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Opportunities
  • Impact Analysis
  • Market Trends
  • Recent Developments
  • Regulatory Scenario
  • Manufacturer Revenue
  • Pricing Analysis
  • Acquisitions and Partnerships Scenario
  • Product Launches/Approvals
  • Fundings and Investments
  • PEST Analysis
  • Porter's Analysis

4. Global Intravenous (IV) Ibuprofen Market- Impact of Coronavirus (COVID-19) Pandemic

  • Overall Impact
  • Government Initiatives
  • COVID-19 Impact on the market

5. Global Intravenous (IV) Ibuprofen Market, By Indication, 2019 - 2031, (USD Bn)

  • Overview
    • Market Share Analysis, 2024 and 2031 (%)
    • Y-o-Y Growth Analysis, 2020 - 2031
    • Segment Trends
  • Pain Management
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
  • Fever
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
  • Others
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

6. Global Intravenous (IV) Ibuprofen Market, By Strength, 2019 - 2031, (USD Bn)

  • Overview
    • Market Share Analysis, 2024 and 2031 (%)
    • Y-o-Y Growth Analysis, 2020 - 2031
    • Segment Trends
  • 100 mg
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
  • 200 mg
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
  • 400 mg
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
  • 800 mg
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

7. Global Intravenous (IV) Ibuprofen Market, By Age Group, 2019 - 2031, (USD Bn)

  • Overview
    • Market Share Analysis, 2024 and 2031 (%)
    • Y-o-Y Growth Analysis, 2020 - 2031
    • Segment Trends
  • Pediatrics
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
  • Adults
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

8. Global Intravenous (IV) Ibuprofen Market, By Distribution Channel, 2019 - 2031, (USD Bn)

  • Overview
    • Market Share Analysis, 2024 and 2031 (%)
    • Y-o-Y Growth Analysis, 2020 - 2031
    • Segment Trends
  • Hospital Pharmacies
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
  • Retail Pharmacies
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
  • Online Pharmacies
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

9. Global Intravenous (IV) Ibuprofen Market, By Region, 2019 - 2031, (USD Bn)

  • Introduction
    • Market Share Analysis, By Region, 2024 and 2031 (%)
    • Y-o-Y Growth Analysis, For Region, 2020-2031
    • Regional Trends
      • North America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Strength, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
      • U.S.
      • Canada
      • Latin America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Strength, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
      • Brazil
      • Mexico
      • Argentina
      • Rest of Latin America
      • Europe
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Strength, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
      • U.K.
      • Germany
      • Italy
      • France
      • Spain
      • Russia
      • Rest of Europe
      • Asia Pacific
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Strength, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
      • China
      • India
      • Japan
      • ASEAN
      • Australia
      • South Korea
      • Rest of Asia Pacific
      • Middle East
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Strength, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
      • GCC
      • Israel
      • Rest of Middle East
      • Africa
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Strength, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2019 - 2031, (USD Bn)
      • North Africa
      • Central Africa
      • South Africa

10. Competitive Landscape

  • Company Profiles
    • Cumberland Pharmaceuticals Inc.
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Hyloris Pharmaceuticals SA
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Grifols, S.A.
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Recordati Rare Diseases Inc.
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • XGEN PHARMACEUTICALS DJB, Inc.
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • AFT Pharmaceuticals
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Laboratorios Valmorca
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • SGPharma Pvt. Ltd.
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Wellona Pharma
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Delex Pharma
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Hikma Pharmaceuticals PLC
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies

11. Analyst Recommendations

  • Wheel of Fortune
  • Analyst View
  • Coherent Opportunity Map

12. References and Research Methodology

  • References
  • Research Methodology
  • About us and Sales Contact